(PODD) Insulet - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45784P1012

Insulin Pump, Automated Delivery, Wireless Pods, Drug Device

Stock: Health Care Equipment
Age 18.7y
MCap 20,252m
Avg Vol 638K (180M USD)
Beta 0.815
Volatility 41.37%

EPS (Earnings per Share)

EPS (Earnings per Share) of PODD over the last years for every Quarter: "2020-12": -0.04, "2021-03": 0, "2021-06": 0.23, "2021-09": 0.18, "2021-12": 0.42, "2022-03": 0.4, "2022-06": -0.5, "2022-09": 0.35, "2022-12": 0.24, "2023-03": 0.23, "2023-06": 0.38, "2023-09": 0.71, "2023-12": 1.4, "2024-03": 0.73, "2024-06": 0.55, "2024-09": 0.9, "2024-12": 1.15, "2025-03": 1.02, "2025-06": 1.17, "2025-09": 1.24, "2025-12": 0,
EPS CAGR: -13.34%
EPS Trend: 54.0%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of PODD over the last years for every Quarter: 2020-12: 246.1, 2021-03: 252.3, 2021-06: 263.2, 2021-09: 275.6, 2021-12: 307.7, 2022-03: 295.4, 2022-06: 299.4, 2022-09: 340.8, 2022-12: 369.7, 2023-03: 358.1, 2023-06: 396.5, 2023-09: 432.7, 2023-12: 509.8, 2024-03: 441.7, 2024-06: 488.5, 2024-09: 543.9, 2024-12: 597.5, 2025-03: 569, 2025-06: 649.1, 2025-09: 706.3, 2025-12: null,
Rev. CAGR: 24.80%
Rev. Trend: 98.1%
Last SUE: 2.47
Qual. Beats: 16

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 41.4%
Value at Risk 5%th 61.0%
Relative Tail Risk -10.32%
Reward TTM
Sharpe Ratio 0.03
Alpha -15.58
CAGR/Max DD -0.03
Character TTM
Hurst Exponent 0.576
Beta 0.815
Beta Downside 1.168
Drawdowns 3y
Max DD 61.31%
Mean DD 24.57%
Median DD 19.89%

Description: PODD Insulet December 19, 2025

Insulet Corporation (NASDAQ:PODD) designs, manufactures, and markets tubeless insulin-delivery systems for people with insulin-dependent diabetes, primarily through its Omnipod platform. The Omnipod 5 combines a proprietary automated insulin-delivery (AID) algorithm with Bluetooth-linked continuous glucose monitoring, while the Omnipod DASH uses a smartphone-style personal diabetes manager to control a Bluetooth-enabled pod. Insulet also supplies pods to Amgen for the Neulasta Onpro chemotherapy kit and distributes its products via pharmacies and independent distributors.

Key recent metrics: FY 2023 revenue reached roughly $2.5 billion, up about 16 % YoY, driven by a ~30 % market-share position in the U.S. tubeless pump segment and expanding adoption of automated insulin delivery. Gross margins have remained high at ~70 %, reflecting the premium nature of the hardware and software bundle, while R&D spending stays near 10 % of revenue to sustain algorithm improvements. A macro driver is the continued rise in diabetes prevalence-over 10 % of U.S. adults-supporting long-term demand for advanced insulin-delivery solutions.

For a deeper quantitative assessment, you may find ValueRay’s platform useful for drilling into Insulet’s valuation metrics and peer comparisons.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income: 246.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.74 > 1.0
NWC/Revenue: 48.05% < 20% (prev 67.31%; Δ -19.26% < -1%)
CFO/TA 0.18 > 3% & CFO 533.7m > Net Income 246.2m
Net Debt (273.9m) to EBITDA (451.2m): 0.61 < 3
Current Ratio: 2.87 > 1.5 & < 3
Outstanding Shares: last quarter (70.7m) vs 12m ago -4.45% < -2%
Gross Margin: 71.46% > 18% (prev 0.69%; Δ 7077 % > 0.5%)
Asset Turnover: 83.30% > 50% (prev 65.57%; Δ 17.73% > 0%)
Interest Coverage Ratio: 6.85 > 6 (EBITDA TTM 451.2m / Interest Expense TTM 53.1m)

Altman Z'' 3.76

A: 0.40 (Total Current Assets 1.86b - Total Current Liabilities 647.7m) / Total Assets 3.03b
B: 0.06 (Retained Earnings 185.8m / Total Assets 3.03b)
C: 0.12 (EBIT TTM 363.7m / Avg Total Assets 3.03b)
D: 0.12 (Book Value of Equity 199.0m / Total Liabilities 1.65b)
Altman-Z'' Score: 3.76 = AA

Beneish M -3.03

DSRI: 0.97 (Receivables 462.2m/375.6m, Revenue 2.52b/1.98b)
GMI: 0.97 (GM 71.46% / 69.36%)
AQI: 0.93 (AQ_t 0.15 / AQ_t-1 0.16)
SGI: 1.27 (Revenue 2.52b / 1.98b)
TATA: -0.09 (NI 246.2m - CFO 533.7m) / TA 3.03b)
Beneish M-Score: -3.03 = AA

ValueRay F-Score (Strict, 0-100) 76.47

1. Piotroski: 9.0pt
2. FCF Yield: 2.05%
3. FCF Margin: 16.70%
4. Debt/Equity: 0.75
5. Debt/Ebitda: 0.61
6. ROIC - WACC: 0.99%
7. RoE: 18.27%
8. Revenue Trend: 98.10%
9. EPS Trend: 53.99%

What is the price of PODD shares?

As of January 25, 2026, the stock is trading at USD 271.60 with a total of 1,662,635 shares traded.
Over the past week, the price has changed by -5.60%, over one month by -4.87%, over three months by -16.03% and over the past year by -2.02%.

Is PODD a buy, sell or hold?

Insulet has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PODD.
  • Strong Buy: 14
  • Buy: 6
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the PODD price?

Issuer Target Up/Down from current
Wallstreet Target Price 373.8 37.6%
Analysts Target Price 373.8 37.6%
ValueRay Target Price 270.9 -0.3%

PODD Fundamental Data Overview January 19, 2026

P/E Trailing = 84.1228
P/E Forward = 47.1698
P/S = 8.0307
P/B = 14.6202
P/EG = 2.1853
Revenue TTM = 2.52b USD
EBIT TTM = 363.7m USD
EBITDA TTM = 451.2m USD
Long Term Debt = 934.9m USD (from longTermDebt, last quarter)
Short Term Debt = 96.4m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 273.9m USD (from netDebt column, last quarter)
Enterprise Value = 20.53b USD (20.25b + Debt 1.03b - CCE 757.4m)
Interest Coverage Ratio = 6.85 (Ebit TTM 363.7m / Interest Expense TTM 53.1m)
EV/FCF = 48.73x (Enterprise Value 20.53b / FCF TTM 421.2m)
FCF Yield = 2.05% (FCF TTM 421.2m / Enterprise Value 20.53b)
FCF Margin = 16.70% (FCF TTM 421.2m / Revenue TTM 2.52b)
Net Margin = 9.76% (Net Income TTM 246.2m / Revenue TTM 2.52b)
Gross Margin = 71.46% ((Revenue TTM 2.52b - Cost of Revenue TTM 719.7m) / Revenue TTM)
Gross Margin QoQ = 72.22% (prev 69.67%)
Tobins Q-Ratio = 6.78 (Enterprise Value 20.53b / Total Assets 3.03b)
Interest Expense / Debt = 1.51% (Interest Expense 15.6m / Debt 1.03b)
Taxrate = 28.66% (35.2m / 122.8m)
NOPAT = 259.4m (EBIT 363.7m * (1 - 28.66%))
Current Ratio = 2.87 (Total Current Assets 1.86b / Total Current Liabilities 647.7m)
Debt / Equity = 0.75 (Debt 1.03b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 0.61 (Net Debt 273.9m / EBITDA 451.2m)
Debt / FCF = 0.65 (Net Debt 273.9m / FCF TTM 421.2m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 246.2m / Total Assets 3.03b)
RoE = 18.27% (Net Income TTM 246.2m / Total Stockholder Equity 1.35b)
RoCE = 15.94% (EBIT 363.7m / Capital Employed (Equity 1.35b + L.T.Debt 934.9m))
RoIC = 9.53% (NOPAT 259.4m / Invested Capital 2.72b)
WACC = 8.54% (E(20.25b)/V(21.28b) * Re(8.92%) + D(1.03b)/V(21.28b) * Rd(1.51%) * (1-Tc(0.29)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.57%
[DCF Debug] Terminal Value 67.80% ; FCFF base≈351.5m ; Y1≈230.7m ; Y5≈105.3m
Fair Price DCF = 22.84 (EV 1.88b - Net Debt 273.9m = Equity 1.61b / Shares 70.3m; r=8.54% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 53.99 | EPS CAGR: -13.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.10 | Revenue CAGR: 24.80% | SUE: 2.47 | # QB: 16
EPS next Quarter (2026-03-31): EPS=1.19 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=18
EPS next Year (2026-12-31): EPS=6.18 | Chg30d=-0.002 | Revisions Net=+2 | Growth EPS=+26.4% | Growth Revenue=+20.5%

Additional Sources for PODD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle